Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.53 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | FNTA | P49354 | 1/20 | 0.41 |
| ▸ | FNTB | P49356 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13949622 | 0.87 | CHRNB2 (0.63) | CHRNB2CHRNA4RIPK1LMNACHRNA7 | |
| SCHEMBL17282122 | 0.82 | CHRNB2 (0.64) | CHRNB2CHRNA4RIPK1CHRNA7ALDH1A1 | |
| SCHEMBL6354990 | 0.80 | RAB9A (0.45) | CHRNB2CHRNA4RIPK1LMNAALDH1A1 | |
| SCHEMBL17886005 | 0.80 | AOC3 (0.44) | RIPK1LMNAALDH1A1L3MBTL1 | |
| SCHEMBL15699208 | 0.79 | CHRNB2 (0.69) | CHRNB2CHRNA4RIPK1LMNACHRNA7 | |
| SCHEMBL17886929 | 0.78 | CHRNB2 (0.53) | CHRNB2CHRNA4RIPK1LMNACHRNA7 | |
| SCHEMBL19750347 | 0.78 | CHRNB2 (0.56) | CHRNB2CHRNA4RIPK1LMNACHRNA7 | |
| SCHEMBL14350222 | 0.76 | CHRNB2 (0.50) | CHRNB2CHRNA4RIPK1CHRNA7ALDH1A1 | |
| SCHEMBL12779113 | 0.75 | CHRNB2 (0.67) | CHRNB2CHRNA4RIPK1LMNACHRNA7 | |
| SCHEMBL17886001 | 0.75 | PKM (0.55) | CHRNB2CHRNA4RIPK1LMNACHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9850276-B2 | Bidentate-binding modulators of LRRK2 and JNK kinases | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-12-26 | — | — | US | disclosed |
| US-20160185818-A1 | BIDENTATE-BINDING MODULATORS OF LRRK2 AND JNK KINASES | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185818-A1 | BIDENTATE-BINDING MODULATORS OF LRRK2 AND JNK KINASES | LRRK2, PINK1, MAP2K3 | CHRNB2 3743/4885CHRNA4 3741/4885RIPK1 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.